Boston Scientific Says Stroke Risk Reduction Device Trial Meets All Endpoints
MT Newswires Live
Mar 30
Boston Scientific (BSX) said Saturday a trial of the Watchman FLX left atrial appendage closure device met all its primary and secondary safety and efficacy endpoints.
The study evaluated the device versus non-vitamin K antagonist oral anticoagulants as a first-line option for stroke risk reduction in patients with non-valvular atrial fibrillation, a heart rhythm disorder.
Results showed that the device provided "statistically superior" protection from bleeding and demonstrated similar efficacy compared with blood thinners, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.